A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
Chronic Lymphocytic Leukemia · Mantle Cell Lymphoma · Follicular Lymphoma · Richter Transformation Lymphoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 2
- Patients
- 189 (planned)
- Started
- Jul 21, 2022
- Main results expected
- May 17, 2029
- Fully finished
- May 17, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of Participants with MCL (Cohort C), FL (Cohort D), and CLL (Cohort D) with ≥1 Adverse Event (AE)
Measured over: Up to approximately 81 months
Percentage of Participants with MCL (Cohort C), FL (Cohort D), and CLL (Cohort D) who Discontinue from Study Therapy Due to AE
Measured over: Up to approximately 81 months
Percentage of Participants with MCL (Cohort C) who Experience a Dose-Limiting Toxicity (DLT)
Measured over: Up to approximately 81 months
Objective Response Rate (ORR) per Lugano Response Criteria as Assessed by Blinded Independent Central Review (BICR) in Participants with MCL (Cohort A), RT (Cohort B), and FL (Cohort D)
Measured over: Up to approximately 81 months
ORR per Lugano Response Criteria as Assessed by Investigator in Participants with MCL (Cohort C)
Measured over: Up to approximately 81 months
ORR per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria as Assessed by Investigator in Participants with CLL (Cohort D)
Measured over: Up to approximately 81 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05458297 · record last updated 2026-08-21 · checked 2026-11-09 15:47 UTC